ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Capricor Therapeutics Inc

Capricor Therapeutics Inc (CAPR)

4.67
0.27
( 6.14% )
Updated: 15:54:45

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
4.67
Bid
4.65
Ask
4.67
Volume
426,472
4.36 Day's Range 4.69
2.68 52 Week Range 8.2212
Market Cap
Previous Close
4.40
Open
4.40
Last Trade Time
15:55:24
Financial Volume
$ 1,919,288
VWAP
4.5004
Average Volume (3m)
447,235
Shares Outstanding
31,811,470
Dividend Yield
-
PE Ratio
-6.67
Earnings Per Share (EPS)
-0.7
Revenue
25.18M
Net Profit
-22.29M

About Capricor Therapeutics Inc

Capricor Therapeutics, Inc. is a San Diego based biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell t... Capricor Therapeutics, Inc. is a San Diego based biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in late-stage clinical development for treating Duchenne muscular dystrophy (DMD). Capricor is also developing its exosome technology as a next-generation therapeutic platform. Capricor's proprietary StealthX¿ exosome platform has potential for a broad range of new therapeutic applications in the field of vaccinology as well as targeted oligonucleotide, protein and small molecule therapeutics to treat or prevent a variety of diseases. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Capricor Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CAPR. The last closing price for Capricor Therapeutics was $4.40. Over the last year, Capricor Therapeutics shares have traded in a share price range of $ 2.68 to $ 8.2212.

Capricor Therapeutics currently has 31,811,470 shares outstanding. The market capitalization of Capricor Therapeutics is $139.97 million. Capricor Therapeutics has a price to earnings ratio (PE ratio) of -6.67.

CAPR Latest News

Capricor Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare...

Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac Function in the HOPE-2 OLE Study in Duchenne Muscular Dystrophy

-Results in Performance of the Upper Limb (PUL v2.0) Continue to Show Slowing of Disease Progression in Later-Stage DMD Patients- -Improvements Seen in Multiple Cardiac Endpoints Demonstrating...

CORRECTION: Capricor Therapeutics

SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- In a release issued under the headline "Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy" on Tuesday, June 25th by...

Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy

SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare...

Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway

--FDA Grants Pre-BLA Meeting Request and Rolling BLA Submission after Review of HOPE-2 and HOPE-2 OLE 3-Year Results-- SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:...

Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

--Results in Performance of the Upper Limb (PUL 2.0) Continue to Show Benefits in Skeletal Muscle Function After 3 Years of CAP-1002 Treatment (p< 0.001)-- --Stabilization in Left Ventricular...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.13-2.708333333334.85.264.234454204.57931481CS
4-0.49-9.496124031015.165.264.236123594.72898955CS
12-0.32-6.41282565134.996.53364.234472355.17489997CS
260.235.180180180184.447.283.563588065.30433342CS
520.214.708520179374.468.22122.682963564.89124694CS
1560.235.180180180184.448.22122.562545264.63013059CS
260-2.48-34.68531468537.1512.320.887737535.9117536CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AAGRAfrican Agriculture Holdings Inc
$ 0.00
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 0.00
(0.00%)
0
AADIAadi Bioscience Inc
$ 0.00
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 0.00
(0.00%)
0
AACGATA Creativity Global
$ 0.00
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.00
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 0.00
(0.00%)
0
AADIAadi Bioscience Inc
$ 0.00
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 0.00
(0.00%)
0
AACGATA Creativity Global
$ 0.00
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.00
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 0.00
(0.00%)
0
AADIAadi Bioscience Inc
$ 0.00
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 0.00
(0.00%)
0
AACGATA Creativity Global
$ 0.00
(0.00%)
0

CAPR Discussion

View Posts
staynafloat staynafloat 1 month ago
--FDA Grants Pre-BLA Meeting Request and Rolling BLA Submission after Review of HOPE-2 and HOPE-2 OLE 3-Year Results--

SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the successful completion of a Type-B meeting with the U.S. Food and Drug Administration (FDA) on next steps for the Biologics License Application (BLA) submission with its lead asset, CAP-1002 for the treatment of Duchenne muscular dystrophy (DMD). Additionally, Deramiocel has been selected as the proposed International Nonproprietary Name (INN) for CAP-1002 by the World Health Organization.

“The last year has been transformative for Capricor as we have moved rapidly towards potential approval for CAP-1002 for the treatment of DMD,” said Linda Marbán, Ph.D., Capricor’s chief executive officer. “The most recent meeting had several very important outcomes; the first of which was that the FDA has agreed to a pre-BLA meeting based on their review of our clinical data from HOPE-2, HOPE-2 open label extension (OLE) and available data from HOPE-3. This key agreement will allow us to begin our BLA filing with a rolling submission planned to initiate in the third quarter of 2024.”

The rolling submission process allows for the submission of pre-agreed components of the BLA to be submitted as they are completed, which can streamline the regulatory review process and de-risk the BLA. Capricor plans to further outline the submission schedule with the FDA in the coming months.

Dr. Marbán continued, “We continue to make significant progress on this program as we are awaiting final data in the fourth quarter of 2024 from our already enrolled HOPE-3 pivotal trial and prepare for potential commercialization, including completion of our commercial manufacturing facility and actively preparing for our pre-BLA meeting and rolling BLA submission. Furthermore, we are looking forward to our presentation of additional 3-year data from our HOPE-2 OLE study at the upcoming PPMD conference which we believe will add further evidence of the efficacy and safety of CAP-1002.”

Deramiocel (CAP-1002) for the treatment of DMD has received Orphan Drug Designation and the regulatory pathway for this drug is supported by RMAT (Regenerative Medicine Advanced Therapy Designation). In addition, if Capricor were to receive FDA marketing approval for Deramiocel for the treatment of DMD, Capricor would be eligible to receive a Priority Review Voucher (PRV) based on its previous receipt of a rare pediatric disease designation. Capricor retains full rights to the PRV, if received.

https://www.capricor.com/investors/news-events/press-releases/detail/281/capricor-therapeutics-announces-positive-type-b-meeting
👍️0
D-bol D-bol 1 month ago
Thank you. Lets hope!!!
👍️0
dia76ca dia76ca 1 month ago
More news this month. Should be good !MO!
👍️0
D-bol D-bol 1 month ago
How is everybody thinking still about this company?
👍️0
dia76ca dia76ca 2 months ago
Institutions have been buying big time!
👍️0
PARker1703 PARker1703 2 months ago
Where is the BlA????
👍️0
staynafloat staynafloat 3 months ago
Capricor announces positive Type-B meeting with FDA for CAP-1002 program for DMD. We will host a webcast to discuss this meeting and the latest program updates on Monday, April 29 at 8:30 am ET. #CAPR #CAP1002 #DMD > Click here to view the press release > https://t.co/cNGDQ7zL34 pic.twitter.com/gVNLVPMJNS— Capricor Therapeutics (@Capricor) April 24, 2024
👍️0
starkd748 starkd748 3 months ago
Lol I sold it for a little profit mon
👍️0
PARker1703 PARker1703 3 months ago
Maybe after a R/S
👍️0
starkd748 starkd748 3 months ago
Thanks looks like 8s coming here
👍️0
enthalpy enthalpy 4 months ago
Nice move on VERI.
👍️0
starkd748 starkd748 4 months ago
I loaded VERI instead
👍️0
starkd748 starkd748 4 months ago
Gl I loaded instead
👍️0
enthalpy enthalpy 4 months ago
Its going to 8 based on the weekly chart.
👍️0
starkd748 starkd748 4 months ago
Fell off a cliff today
👍️0
ed3/6me ed3/6me 4 months ago
Sold last at 6 bought bach at 4 so have a few more shares. Not like Enthalpy
👍️0
GreedyAgorist GreedyAgorist 4 months ago
You did not sell at 6 this time around, I hope. : - )
I added some shares under 6, because waiting for a big dip was not working. Patience is a virtue or so I've heard, but... I've had to add more 7.5 strikes to my options orders. I thought we could enjoy hanging around 5 for a while, but this thing is not accommodating that plan.

Is everyone enjoying this steady climb? We are just pennies away from being 100% up from the low for the year and yet this ticker is not on the breakout board. Which is good. Hitting #1 on the Hot Board is nearly always a sell signal.
👍️0
starkd748 starkd748 4 months ago
Haha looks like it
👍️0
enthalpy enthalpy 4 months ago
I think it get to 8 next week or so. We will see!!! Gltu!!!
👍️0
starkd748 starkd748 4 months ago
I'm waiting for 4s for a flip lol...Looks bearish
👍️0
enthalpy enthalpy 4 months ago
I doubled my position in the 4s. We will see. Secretly hoping for a green light on AA BLA in some form. So many other companies have a 500 million or billion dollar market cap and capr is right there but beaten down. At point it will get discovered.
👍️0
Volcano Volcano 4 months ago
I told you all
1000% runner here
👍️0
ed3/6me ed3/6me 4 months ago
would be a bigger player with my other holdings cooperation. Do not have volcanos view but feel it is a great vehicle for slow steady progress.
👍️0
enthalpy enthalpy 4 months ago
Hey Ed this is probably going to 8 this month at a minimum. Fingers crossed.
👍️0
ed3/6me ed3/6me 4 months ago
Sold some at 6 re bought at 4 so more shares and money
👍️0
GreedyAgorist GreedyAgorist 4 months ago
How did that work out for you, ed? Did you get some 5's assigned to you last month? I only picked up another 100 shares in February, after doing the same in January. It was December when I increased my position here by 60%. Now all those shares are up for grabs at 5. We will find out in 10 days if that is a bargain or not. At worst it will be a 25% gain in 3 months.

I only have one position in cash covered puts. Those will also expire on the 15th. It will be like scoring a 20% dividend out of something that does not pay a dividend.* Wish I had more put positions; I will the next time this "pos" dips. BTW, I trade this in an IRA, so no Wash Sale worries. I won't presently become a millionaire like Volcano. But maybe future me will.

Obvious statement: I am not ed3/6me's financial advisor or anyone else's. Just demonstrating how you can milk a ticker for almost monthly income without it being a blue chip dividend payer. I can't say it removes those anxious feelings you get when it dumps (or pumps), but it will remove some cash off the table.

*I could use more such scores to keep up with inflation; you know, just in case Biden scapegoating evil corporations doesn't do the trick.
👍️0
staynafloat staynafloat 5 months ago
Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy

SAN DIEGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- – Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, announced today that the Company has been granted an in-person Type-B meeting with the U.S. Food & Drug Administration (FDA) scheduled for late March. In the upcoming meeting with the FDA, the Company intends to discuss its proposed chemistry, manufacturing and controls (CMC) plans for commercial launch, if approved which may enable opportunities to expedite the pathway to a Biologics License Application (BLA) submission. The Company has previously been granted Regenerative Medicine Advanced Therapy (RMAT) and orphan drug designations for the use of CAP-1002 in Duchenne muscular dystrophy (DMD) and these designations enable sponsors to work closely with the FDA and receive its guidance on potential expedited pathways for approval.

“At this time, with our pivotal Phase 3, HOPE-3 trial fully enrolled in Cohort A and top-line data expected in the fourth quarter of this year, we believe that discussing our CMC plans for potential commercialization with the FDA will allow us the opportunity to bring CAP-1002 to patients in the most expeditious manner possible for patients in need,” said Linda Marbán, Ph.D., Capricor’s chief executive officer. “At Capricor, we remain focused on getting to approval as quickly as possible and we look forward to providing more details after this meeting.”

https://www.capricor.com/investors/news-events/press-releases/detail/271/capricor-therapeutics-announces-upcoming-type-b-meeting
👍️0
steadykickin steadykickin 5 months ago
https://www.capricor.com/investors/news-events/press-releases/detail/270/capricor-therapeutics-to-present-fourth-quarter-and-full February 29.
👍️0
Boom2013 Boom2013 5 months ago
https://www.capricor.com/investors/news-events/press-releases/detail/269/capricor-therapeutics-announces-manufacturing-scale-up-of
👍️0
steadykickin steadykickin 5 months ago
Capricor is pleased to be featured in a Scientific Session being held today at the International Duchenne Parent Project Italy Conference in Rome. To view the full agenda and additional details on the session please, click here: https://t.co/nOg382Rcj3 pic.twitter.com/pNg2sdUuHk— Capricor Therapeutics (@Capricor) February 17, 2024
👍️0
ed3/6me ed3/6me 5 months ago
Wrong
👍️0
stockplayer-11 stockplayer-11 5 months ago
Looks like nobody is interested in this shitty scam that'll never see FDA approval
👍️0
stockplayer-11 stockplayer-11 5 months ago
Damn your dumb ass can't even form a complete sentence.
👍️0
Volcano Volcano 5 months ago
Bcs you are ignorant and dumb
Why do you think huge Japanese bio firm made a deal?
They are much smarter than you dumbo
👍️0
stockplayer-11 stockplayer-11 5 months ago
You will not be be a millionaire. Will be no FDA approvals. You've been warned
👍️0
Volcano Volcano 5 months ago
I have huge shares here
I will be multi millionaire this year
I am so happy to hold long term
This is the year for FDA approval
👍️0
Volcano Volcano 5 months ago
It is coming
Be patient
We will be millionaires this year
$100 upon FDA approval
👍️0
PARker1703 PARker1703 5 months ago
When????? Been holding this pos for two years
👍️0
Volcano Volcano 6 months ago
Super huge news
👍️ 1
enthalpy enthalpy 6 months ago
K.
👍️0
PARker1703 PARker1703 6 months ago
Because the pumpers stopped posting
👍️0
enthalpy enthalpy 6 months ago
Fda meeting will happening shortly. Hopefully the get the greenlight this time.
👍️ 1
enthalpy enthalpy 6 months ago
On what grounds?
👍️0
ed3/6me ed3/6me 6 months ago
This unfunded part is their actual worth. If it gets teeth...they are going to the moon
👍️0
peterus peterus 6 months ago
going under 3s next few weeks
👍️0
dia76ca dia76ca 6 months ago
Steady progress on DMD is great. But the elephant in the room are the partnerships for the Exosome platforms.
Here is what the company has said...
"Exosome-Based Therapeutics and Vaccines (Preclinical): We are focused on developing a precision-engineered exosome platform technology that has the ability to deliver defined sets of effector molecules which exert their effects through defined mechanisms of action. We recently published preclinical data on our StealthXTM platform showing the rapid development of a recombinant protein-based.... At this time, we are developing vaccines and therapeutics for infectious diseases, monogenic diseases and other potential indications. Our platform builds on advances in fundamental RNA and protein science, targeting technology and manufacturing, providing us the opportunity to potentially build a broad pipeline of new therapeutic candidates. Our current strategy is FOCUSED on SECURING PARTNERS who will provide capital and additional resources..."
👍️0
dia76ca dia76ca 6 months ago
I forgot to add that they will also earn a Priority Review Voucher (PRV) which have sold recently for $110 million.
👍️0
enthalpy enthalpy 6 months ago
Lol well im okay with it. No reason really to go down. Ill hold out Q4 is almost here.
👍️0
dia76ca dia76ca 6 months ago
The recent $10 million milestone is only the start. There is another $90 million coming upon approval. And another $600 million in future milestones. And the ROW rights outside US and Japan should be significant. And very few shares out. Future exosome partnerships could be huge...with buy-out potential anytime IMO.
👍️0
peterus peterus 6 months ago
sell the news lol
👍️0

Your Recent History

Delayed Upgrade Clock